Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.20.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Total revenues $ 18,385 $ 21,906 $ 48,023 $ 49,808
Americas [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 5,841 2,706 17,972 9,620
EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 4,889 12,205 14,175 24,672
APAC [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 7,655 6,995 15,876 15,516
Product Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 9,984 11,555 30,018 25,220
Performance Enzymes [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 13,005 20,424 31,385 41,100
Performance Enzymes [Member] | Americas [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 3,209 2,706 7,381 9,620
Performance Enzymes [Member] | EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 2,141 10,723 8,128 15,964
Performance Enzymes [Member] | APAC [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 7,655 6,995 15,876 15,516
Performance Enzymes [Member] | Product Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 8,401 10,351 18,005 24,588
Performance Enzymes [Member] | Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 4,604 10,073 13,380 16,512
Novel Biotherapeutics [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 5,380 1,482 16,638 8,708
Novel Biotherapeutics [Member] | Americas [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 2,632 0 10,591 0
Novel Biotherapeutics [Member] | EMEA [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 2,748 1,482 6,047 8,708
Novel Biotherapeutics [Member] | APAC [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics [Member] | Product Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues $ 5,380 $ 1,482 $ 16,638 $ 8,708